Ascentage Pharma Group International (NASDAQ:AAPG - Get Free Report)'s share price shot up 5.9% during mid-day trading on Thursday . The stock traded as high as $25.87 and last traded at $25.87. 2,789 shares changed hands during mid-day trading, a decline of 95% from the average session volume of 60,452 shares. The stock had previously closed at $24.43.
Wall Street Analyst Weigh In
Separately, JPMorgan Chase & Co. assumed coverage on Ascentage Pharma Group International in a report on Thursday, March 27th. They issued an "overweight" rating on the stock.
View Our Latest Research Report on Ascentage Pharma Group International
Ascentage Pharma Group International Price Performance
The stock's 50-day moving average is $22.70.
Institutional Investors Weigh In On Ascentage Pharma Group International
A hedge fund recently bought a new stake in Ascentage Pharma Group International stock. Monashee Investment Management LLC purchased a new stake in Ascentage Pharma Group International (NASDAQ:AAPG - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 159,942 shares of the company's stock, valued at approximately $3,511,000. Monashee Investment Management LLC owned 0.18% of Ascentage Pharma Group International at the end of the most recent quarter.
Ascentage Pharma Group International Company Profile
(
Get Free Report)
Ascentage Pharma Group International Co, Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.
Featured Articles
Before you consider Ascentage Pharma Group International, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ascentage Pharma Group International wasn't on the list.
While Ascentage Pharma Group International currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
